Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730282 | 0.92 | LMNA (0.47) | BACE1ALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL30418230 | 0.88 | CYP3A4 (0.46) | BACE1ALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL17477633 | 0.88 | CYP3A4 (0.46) | BACE1ALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL7225274 | 0.88 | ALDH1A1 (0.56) | BACE1ALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL19623132 | 0.88 | GRM5 (0.51) | BACE1ALDH1A1KDM4EMAPTRECQL | |
| SCHEMBL29660333 | 0.87 | BACE1 (0.44) | BACE1ALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL403075 | 0.87 | BACE1 (0.44) | BACE1ALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL2088551 | 0.87 | CYP3A4 (0.45) | BACE1ALDH1A1KDM4EMAPTCYP3A4 | |
| SCHEMBL28418121 | 0.84 | TERT (0.44) | BACE1ALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL3938173 | 0.84 | BACE1 (0.42) | BACE1ALDH1A1KDM4EGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | disclosed |
| WO-2019149965-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITE DE STRASBOURG (FR) | 2019-08-08 | — | — | WO | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016120808-A1 | HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120808-A1 | HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-08-04 | — | — | WO | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
| EP-0739345-B1 | CYCLIC POLYAMINES | ANORMED INC (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-5698546-A | Cyclic polyamines | JOHNSON MATTHEY PUBLIC LIMTED COMPANY (GB) | 1997-12-16 | — | — | US | disclosed |
| EP-0739345-A1 | CYCLIC POLYAMINES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018808-A1 | CYCLIC POLYAMINES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | BACE1 3964/4885ALDH1A1 917/4885KDM4E 2441/4885 |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | BACE1 2842/4885ALDH1A1 323/4885KDM4E 1682/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | BACE1 2294/4885ALDH1A1 990/4885KDM4E 1324/4885 |
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | AFF2, AFF4, AFF1 | BACE1 2141/4885ALDH1A1 1490/4885KDM4E 840/4885 |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | AFF2, AFF4, AFF1 | BACE1 2141/4885ALDH1A1 1490/4885KDM4E 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.